ImmuCell Q3 Sales Jump 46% to $8M on Broad Product Growth
ICCC has more than doubled off its 52-week low of $4.52.
Summary
ImmuCell reported preliminary Q3 2026 sales of $8.0 million, up 46% year-over-year, driven by broad growth across its calf health portfolio. Tri-Shield led with a 51% increase, followed by Dual-Force at 36% and the functional feed line at 37%. Nine-month sales reached $25.6 million, up 27.8%. Management attributed the strong quarter to sales team expansion and improved manufacturing reliability, while noting the comparison was aided by depressed Q3 2025 sales due to high distributor purchases in Q2 2025. The company also announced it will discontinue early sales reporting and will discuss full results on a November 13 conference call.
At the time of this announcement, ICCC was trading at $10.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $87.2M. The 52-week trading range was $4.52 to $12.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.